Challice L. Bonifant

Author

Also Known As

Bonifant, C.L., C Bonifant, C. Bonifant, Challice Bonifant, Challice L Bonifant, Challice L. Bonifant, Challice Lee Bonifant

142

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine University of Michigan Baylor College of Medicine

About

Challice L. Bonifant is an author at Johns Hopkins University specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	598
2	Natural Sciences	3	3	223
3	Biochemistry	3	3	222
4	Public Health	2	2	51
5	Health Sciences	1	1	15

Challice L. Bonifant

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Paul J. Shami, Joseph E. Saavedra, Lai Y. Wang, PubMed Bioorganic ChemistryChemoprevention StrategyNitric OxideCell DeathLeukemia Cells	2003	161
Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA Jung-Sik Kim, Carolyn Lee, Challice L. Bonifant, Molecular and Cellular Biology Cell RegulationHuman CellsPten DeletionHct116 PtenMedicine	2006	156
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities Ilias Christodoulou, Won Jin Ho, Andrew Marple, Journal for ImmunoTherapy of Cancer	2021	147
Antitumor Activity of JS-K [<i>O</i><sup>2</sup>-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related <i>O</i><sup>2</sup>-Aryl Diazeniumdiolates in Vitro and in Vivo Paul J. Shami, Joseph E. Saavedra, Challice L. Bonifant, Journal of Medicinal Chemistry	2006	107
The Secondary Amine/Nitric Oxide Complex Ion R<sub>2</sub>N[N(O)NO]<sup>-</sup> as Nucleophile and Leaving Group in S<sub>N</sub>Ar Reactions Joseph E. Saavedra, Aloka Srinivasan, Challice L. Bonifant, The Journal of Organic Chemistry	2001	97
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia Challice L. Bonifant, Árpád Szöőr, David Torres, Molecular Therapy	2016	80
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells Sergey N. Zolov, Skyler P. Rietberg, Challice L. Bonifant Cytotherapy Cd28.car–t CellsAdaptive Immune SystemMedicineApoptosisImmunology	2018	76
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation Jie Liu, Chengxiu Li, Wei Qu, Molecular Cancer Therapeutics	2004	67
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies Mireya Paulina Velasquez, David Torres, Kota Iwahori, Scientific Reports	2016	56
Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection Ilias Christodoulou, Ruyan Rahnama, Jonas W. Ravich, Frontiers in Immunology MedicineViral ImmunityImmunologyViral PathogenesisAntiviral Therapy	2021	45

Page 1